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Abstract:  
We examined whether an increase in high-sensitivity C-reactive protein (hs-CRP) after percutaneous coronary 
intervention (PCI) predicts long-term prognosis in patients with stable angina pectoris. hs-CRP is an 
inflammatory marker that predicts future cardiovascular events in healthy subjects and patients with unstable and 
stable coronary syndromes. Long-term evaluation of pre- and postprocedural inflammatory markers has not been 
widely reported. In particular, the effect of the magnitude of increase in hs-CRP after PCI in stable patients is 
unknown. We prospectively analyzed 89 stable patients treated by PCI for stable angina pectoris. Patients were 
recruited between August 1998 and May 1999, and the population was followed until August 2005 (mean 
follow-up 79.5 ± 10.3 months). A major adverse cardiac event (MACE) was defined as the occurrence of cardiac 
death, myocardial infarction, or recurrent angina requiring repeat PCI or coronary artery bypass grafting. During 
the follow-up period, 36 patients presented with ≥1 MACE. In multivariate analysis, independent predictors of 
the occurrence of MACEs were previous myocardial infarction and a significant increase in hs-CRP after PCI (p 
= 0.004 and 0.003, respectively). A significant increase in hs-CRP after PCI was found to be more predictive of 
MACEs than hs-CRP before and after PCI. In conclusion, in stable coronary artery disease, inflammation is 
associated with long-term adverse events, but the magnitude of the inflammatory reaction after PCI appears more 
predictive than the baseline value.     
 
A previous study1 has reported that high-sensitivity C-reactive protein (hs-CRP) increases after percutaneous 
coronary intervention (PCI) in patients with unstable angina pectoris and high baseline hs-CRP levels, but not in 
those with normal baseline hs-CRP. An increase in hs-CRP levels after PCI in this unstable condition does not 
seem to be related to the treated plaque but may rather be a marker of the inflammatory state. In stable coronary 
artery disease, it is unknown whether the magnitude of increase in hs-CRP after PCI provides independent 
prognostic information. The purposes of this study were to analyze the long-term prognostic importance of pre- 
and postprocedural hs-CRP and of the magnitude of hs-CRP increase in patients treated by elective PCI for 
stable angina pectoris. 
 
Methods and Results  
Between August 1998 and May 1999, we prospectively analyzed 89 consecutive patients who were referred for 
coronary angiography for stable angina and exercise-induced ischemia. They underwent PCI of ≥1 coronary 
stenosis. Exclusion criteria were age ≥80 years, history of acute coronary syndrome with or without ST-segment 
elevation within the previous year, treatment for restenosis, coronary artery bypass grafting, or PCI within the 
previous 6 months, heart failure of New York Heart Association class ≥3, or known malignant or inflammatory 
disorders. Six-year follow-up was obtained in all patients by inspection of medical records. To ensure that no 
deaths were missed, the general practitioner was contacted to provide clinical evolution and treatment regimens, 
and if the patient had died, to specify cause of death. Major adverse cardiac events (MACEs) were defined as the 
occurrence of cardiac death, myocardial infarction, unstable angina, and any coronary revascularization (surgery 
and/or PCI). Myocardial infarction was defined as the occurrence of typical chest pain associated with an 
increase in creatine kinase-MB ≥3 three times above the upper normal limit or with the development of new 
pathologic Q waves on electrocardiography. The study was approved by the local ethics committee, and all 
patients gave informed consent. 
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A fasting morning blood sample was taken from each patient on the day before and 24 hours after PCI. Multiple 
biologic parameters were studied and are listed in Table 1. hs-CRP assays were measured by rate nephelometry 
using a commercially available kit (Behring N latex C-reactive protein mono Analyzer, Behring Diagnostic, 
Marburg, Germany). The lower detection limit was 0.175 mg/L. Because in epidemiologic studies differences of 
3 mg/L distinguish patients of low, intermediate, and high risk,2-5 an increment in hs-CRP after PCI (Δhs-CRP) 
≥3 mg/L was considered significant. 
Selective coronary angiography was performed through the femoral route using a 6Fr introducer sheath. Serial 
coronary angiograms of the left and right coronary arteries were obtained after intracoronary administration of 
isosor-bide dinitrate (0.2 to 0.4 mg). After diagnostic evaluation, PCI with or without stenting was performed. 
Heparin (70 U/kg) was given before introduction of the guidewire. No patient received glycoprotein Πb/IIIa 
inhibitors, but all were pretreated with ticlopidine (500 mg) ≥4 hours before intervention. All patients were 
treated with aspirin indefinitely, and 250 mg of ticlopidine 2 times daily was added for 4 weeks in patients 
treated by stenting. 
 
Table 1: Characteristics of the population 
Variable Before PCI 
(n = 89) 
After PCI 
(n = 89) 
∆ (after — before) 
(n = 89) 
Age (yrs) 60.2 ± 10.2  Not applicable 
Body mass index (kg/m2) 27.6 ± 3.4  Not applicable 
Men 67 (75.3%)  Not applicable 
Current smoker 48 (53.9%)  Not applicable 
Diabetes mellitus 16 (18%)  Not applicable 
Hypertension 48 (53.9%)  Not applicable 
Previous myocardial infarction 23 (25.8%)  Not applicable 
Previous coronary artery bypass 
grafting 
8 (9%)  Not applicable 
Previous PCI 24 (27%)  Not applicable 
Statin treatment 16 (18%) 80 (90%) 64 
Ejection fraction <50% 10 (11.2%)  Not applicable 
Stent 57 (64%)  Not applicable 
Folic acid (ng/ml) 6 ± 2.35  Not available 
Homocysteine (µmol/L) 11 ± 4.2  Not available 
Fibrinogen (g/L) 2.88 ± 0.7 3.17 ± 0.6 0.29 
Total creatine kinase (UI/L) 91.7 ± 46.3 135.39 ± 113.8 43.69 
Creatine kinase-MB (µg/L) 2.01 ± 1.2 6.74 ± 9.4 4.73 
Myoglobin (µg/L) 20.38 ± 14.3 38.17 ± 57.1 17.79 
Troponin T (µg/L) 0.01 0.11 ± 0.3 0.1 
hs-CRP (mg/L) 3.35 ± 5.1 8.69 ± 8.8 5.34 
Triglycerides (mg/dl) 217 ± 160 226 ± 150 9 
Total cholesterol (mg/dl) 218 ± 40 209 ± 40 -9 
LDL cholesterol (mg/dl) 134 ± 30 127 ± 40 -7 
Apolipoprotein Al (mg/dl) 121 ± 20 133 ± 20 12 
Apolipoprotein B (mg/dl) 104 ± 20 106 ± 20 2 
Lipoprotein (a) (mg/dl) 23 ±30 25 ±30 2 
Oromucosoid (g/L) 0.74 ± 0.2 0.92 ± 0.2 0.18 
Values expressed as means ± SDs for age and body mass index and as means ± SEMs for other values. LDL = low-density lipoprotein. 
 
Continuous variables are expressed as mean ± 1 SD. Differences between mean values were assessed by 
Student's t test (for normally distributed variables) and by the nonparametric Kruskal-Wallis test for other 
variables. Categorical variables were compared with chi-square test. The Kaplan-Meier method was used for 
cumulative MACE-free survival analysis. The effect of covariates on survival times was tested by Cox 
proportional hazards regression analysis. Correlation between quantitative variables was assessed by means of 
Spearman's correlation coefficient. Cut-off points of differences between CRP values before and after 
intervention were derived by the likelihood ratio procedure. Results were considered significant at the 5% critical 
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level (p <0.05). All calculations were performed with SAS 9.1 for Windows (SAS Institute, Cary, North 
Carolina) and S-PLUS 6.2 (Insightful Corporation, Seattle, Washington). 
Clinical, biological, and angiographic characteristics of the studied population are listed in Table 1. 
Angiographic procedural success was obtained in all patients, with no in-hospital complications. 
Median hs-CRP levels were 3.35 mg/L before intervention and 8.69 mg/L after PCI. Most patients presented 
with at least a slight increase in this parameter (mean Δhs-CRP 5.34 mg/L). A significant Δhs-CRP after PCI (≥3 
mg/L) was observed in 43 patients. 
To evaluate whether intense inflammatory reaction was linked to embolization and minor myocardial damage, 
we compared changes in hs-CRP and troponin T. There was no correlation between a Δhs-CRP level >3 mg/L 
and a Δtro-ponin T level >0.0l µg/L (Figure 1). 
Patients showing a Δhs-CRP level >3 mg/L after PCI had a higher incidence of previous myocardial infarction 
and a lower ejection fraction. Mean fibrinogen values before and after PCI were also higher in these patients, 
who otherwise did not differ from patients without a significant increase in hs-CRP after PCI (Table 2). 
During follow-up, 36 patients presented with 1 MACE: 1 patient died of cardiac cause (sudden death); 6 patients 
presented with acute myocardial infarction (2 with Q wave and 4 with non-Q wave); 6 patients underwent 
coronary bypass grafting for recurrent ischemia; 12 patients were treated by PCI on a lesion other than the initial 
lesion; and 11 patients presented with symptomatic restenosis that was treated by repeat PCI. Of these, 33 events 
occurred in patients with a significant Δhs-CRP level, and only 3 events happened in patients with a Δhs-CRP 
level <3 mg/L. 
Figure 2 presents Kaplan-Meier event-free survival curves in patients with or without a significant increase in hs-
CRP after PCI. The higher rate of events in patients with a Δhs-CRP level >3 mg/L was observed throughout the 
follow-up period at 1 year (18% vs 2.2%, p <0.000l) and after 6.6 years (37% vs 3.4%, p <0.000l). 
Univariate predictors of MACEs were previous myocardial infarction, left ventricular ejection fraction <50%, 
ab-normal values after PCI in myoglobin and hs-CRP, and a Δhs-CRP level >3 mg/L. In multivariate analysis, 
previous myocardial infarction and a Δhs-CRP level >3 mg/L were independent predictors of long term-outcome 
(p = 0.004 and 0.003, respectively; Table 3). 
An increase in hs-CRP level >3 mg/L after PCI had a higher predictive value for the occurrence of MACEs than 
hs-CRP before and after PCI considered separately. The Kaplan-Meier event-free survival curve according to hs-
CRP and troponin T variations is presented in Figure 3. 
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Table 2: Comparison between patient groups according to level of change in high-sensitivity C-reactive protein 
Change in CRP After Intervention Variable 
<3 mg/L (n = 46) ≥3 mg/L (n = 43) 
p Value 
Age (yrs) 59.9 ± 9.4 60.5 ± 11.1 0.80 
Men 38 (83%) 29 (67%) 0.097 
Smoker 25 (54%) 23 (53%) 0.94 
Diabetes mellitus 8 (17%) 8 (19%) 0.88 
Hypertension 25 (54%) 23 (53%) 0.94 
Previous myocardial infarction 7 (15%) 16 (37%) 0.018* 
Previous coronary artery bypass 
grafting 
2 (4%) 6 (14%) 0.11 
Previous PCI 12 (26%) 12 (28%) 0.85 
Statins 9 (20%) 7 (16%) 0.69 
Ejection fraction ≤50% 2 (4%) 8 (19%) 0.033* 
Stent 30 (65%) 27 (63%) 0.81 
Height (cm) 170 ± 7.8 169 ± 9.2 0.71 
Weight (kg) 80 ± 11 79 ± 12 0.63 
Before PCI 
Fibrinogen (g/L) 2.7 ± 0.60 3.1 ± 0.76 0.032* 
Creatine kinase (UI/L) 94 ± 48 89 ±44 0.65 
Creatine kinase-MB (µg/L) 2.0 ± 1.1 2.1 ± 1.2 0.58 
Myoglobin (µg/L) 20.2 ± 11.5 20.5 ± 17.0 0.92 
Troponin T >0.01 µg/L 2 (4%) 1 (2%) 0.60 
Lipoprotein (a) (mg/dl) 24 ±26 23 ±27 0.94 
After PCI 
Fibrinogen (g/L) 3.0 ± 0.67 3.4 ± 0.48 0.0077* 
Creatine kinase (UI/L) 124 ± 94.6 148 ± 131 0.34 
Creatine kinase-MB (µg/L) 5.5 ± 6.3 8.0 ± 12 0.22 
Myoglobin (µg/L) 26.5 ± 16.2 50.6 ± 79.1 0.056 
Troponin T (µg/L) 0.08 ± 0.14 0.14 ± 0.39 0.36 
Change in troponin T 0.07 ± 0.14 0.13 ± 0.39 0.36 
Lipoprotein (a) (mg/dl) 26 ± 29 25 ± 30 0.89 
* p <0.05. 
 
Discussion 
The main findings of this study follow. In patients with stable angina pectoris who underwent PCI, the incidence 
of MACEs is higher in those with a significant increase in hs-CRP (>3 mg/L) after PCI in short- and long-term 
follow-up (18% vs 2.2% at 1 year and 37% vs 3.4% at a mean of 6.6 years, respectively). The 2 independent 
predictors of complications are a hs-CRP increase after PCI and previous myocardial infarction. A hsCRP 
increase induced by PCI yields a higher predictive value for MACEs than hs-CRP before or after PCI considered 
separately. 
In stable patients, PCI triggers an inflammatory response that is not observed in patients undergoing coronary 
angiography without PCI.6 
Increased CRP in this setting is not related to minor myocardial necrosis because we found no correlation 
between significant increases in hs-CRP and troponin T concentrations after PCI. A previous study found that 
patients with high inflammatory parameters at baseline were more likely to develop increased troponin, 
indicative of myocardial cell damage.7 Thus, patients presenting with a high level of inflammatory markers 
before PCI appear to be more prone to develop microembolizations. This could explain the prognostic 
importance of CRP at baseline, at least for short- and mid-term outcomes. 
Several reports have indicated that hs-CRP provides additional and independent prognostic information to the 
clinical and angiographic characteristics in patients undergoing PCI. In a large series of 727 patients treated by 
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PCI, most with stent implantation and glycoprotein Πb/IIIa inhibitor infusion, hs-CRP predicted 30-day 
complications.8 In a population of 501 patients treated by elective angioplasty for stable coronary artery disease 
in whom stents and glycoprotein Πb/IIIa inhibitors were less frequently used, a hs-CRP level >3 mg/L was also a 
strong predictor of 2-year adverse coronary events.9 In a cohort of 1,152 patients with stable angina treated by 
coronary stenting and followed for 1 year, Dibra et al10 reported that a CRP level >5 mg/L was associated with 
an increased risk of death and myocardial infarction but had no effect on restenosis. Although these studies 
included large populations, they analyzed a relatively short-term outcome. Further, the use of different cut-off 
values of hs-CRP in these studies limits their application in clinical practice. 
Figure 2. Event-free survival curves of patients with and without a significant increase in hs-CRP after PCI. 
 
 
Table 3 Predictors of major adverse cardiac events in univariate and multivariate analyses 
 Univariate Analysis Multivariate Analysis  
p Value Hazard Ratio (95% CI) p Value Hazard Ratio (95% CI) 
Previous myocardial infarction 0.0002 3.5 (1.8-6.8) 0.004 2.80(1.4-5.64) 
Left ventricular ejection fraction 
<50% 
0.01 2.8 (1.2-6.5) NS  
Myoglobin after PCI 0.05 1.004(1-1.008) NS  
hs-CRP after PCI 0.0002 1.05 (1.02-1.07) NS  
Δhs-CRP <0.0001 21.3 (6.5-70.3) 0.003 1.05 (1.02-1.09) 
CI = confidence interval. 
 
Late cardiac events usually result from the progression of atherosclerosis rather than from a complication of the 
PCI procedure (e.g., restenosis). Therefore, we think that it is crucial to extend the event horizon beyond 6 or 12 
months to a longer period, as in the present study. Our study with a long-term follow-up confirms the strong 
prognostic effect of inflammation. This effect was not confined to the short term after PCI but was observed 
throughout the entire 6-year follow-up. 
Although the level of inflammatory markers at baseline is clinically significant, the most powerful predictor of a 
worse outcome was the increase in such markers after PCI. A high hs-CRP level after PCI observed in some 
patients may reflect the hyper-responsiveness of their inflammation system to vascular aggression. Such hyper-
reactivity ap pears to be a marker of increased progression of atherosclerosis and/or further clinical instability. 
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This study involved a limited population. No drug-elut-ing stents were used. All patients in this study were in a 
stable condition. Our observations are not necessary applicable to other clinical settings. 
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